Riccardi R, Riccardi A, Lasorella A, Di Rocco C, Carelli G, Tornesello A, Servidei T, Iavarone A, Mastrangelo R
Division of Pediatric Oncology, Catholic University of Rome, Italy.
Cancer Chemother Pharmacol. 1994;33(6):477-83. doi: 10.1007/BF00686504.
The present study was undertaken to evaluate in children the plasma pharmacokinetics of free carboplatin given at different doses and schedules and to evaluate the inter- and intrapatient variability and the possible influence of schedule on drug exposure. A total of 35 children (age range, 1-17 years) with malignant tumors were studied. All patients had normal renal function (creatinine clearance corrected for surface body area, above 70 ml min-1 m-2; range, 71-151 ml min-1 m-2) and none had renal involvement by malignancy. Carboplatin was given at the following doses and schedules: 175, 400, 500, and 600 mg/m2 given as as a 1-h infusion; 1,200 mg/m2 divided into equal doses and infused over 1 h on 2 consecutive days; and 875 and 1,200 mg/m2 given as a 5-day continuous infusion. A total of 57 courses were studied. Carboplatin levels in plasma ultrafiltrate (UF) samples were measured both by high-performance liquid chromatography and by atomic absorption spectrophotometry. Following a 1-h infusion, carboplatin free plasma levels decayed biphasically; the disappearance half-lives, total body clearance, and apparent volume of distribution were similar for different doses. In children with normal renal function as defined by creatinemia and blood urea nitrogen (BUN) and creatinine clearance, we found at each dose studied a limited interpatient variability of the peak plasma concentration (Cmax) and the area under the concentration-time curve (AUC) and a linear correlation between the dose and both Cmax (r = 0.95) and AUC (r = 0.97). The mean value +/- SD for the dose-normalized AUC was 13 +/- 2 min m2 l-1 (n = 57).2+ The administration schedule does not seem to influence drug exposure, since prolonged i.v. infusion or bolus administration of 1,200 mg/m2 achieved a similar AUC (13.78 +/- 2.90 and 15.05 +/- 1.44 mg ml-1 min, respectively). In the nine children studied during subsequent courses a limited interpatient variability was observed and no correlation (r = 0.035) was found between AUC and subsequent courses by a multivariate analysis of dose, AUC, and course number. The pharmacokinetic parameters were similar to those previously reported in adults; however, a weak correlation (r = 0.52, P = 0.03) between carboplatin total body clearance and creatinine clearance varying within the normal range was observed.(ABSTRACT TRUNCATED AT 400 WORDS)
本研究旨在评估不同剂量和给药方案下儿童游离卡铂的血浆药代动力学,评估患者间和患者内的变异性以及给药方案对药物暴露的可能影响。共研究了35例患有恶性肿瘤的儿童(年龄范围为1至17岁)。所有患者肾功能正常(根据体表面积校正的肌酐清除率高于70 ml·min⁻¹·m⁻²;范围为71至151 ml·min⁻¹·m⁻²),且无恶性肿瘤累及肾脏。卡铂的给药剂量和方案如下:175、400、500和600 mg/m²,静脉输注1小时;1200 mg/m²分为等份剂量,连续2天每天静脉输注1小时;875和1200 mg/m²持续静脉输注5天。共研究了57个疗程。通过高效液相色谱法和原子吸收分光光度法测量血浆超滤液(UF)样本中的卡铂水平。静脉输注1小时后,游离卡铂血浆水平呈双相衰减;不同剂量的消除半衰期、全身清除率和表观分布容积相似。在根据血肌酐、血尿素氮(BUN)和肌酐清除率定义为肾功能正常的儿童中,我们发现在每个研究剂量下,血浆峰浓度(Cmax)和浓度-时间曲线下面积(AUC)的患者间变异性有限,且剂量与Cmax(r = 0.95)和AUC(r = 0.97)之间呈线性相关。剂量标准化AUC的平均值±标准差为13±2 min·m²·l⁻¹(n = 57)。给药方案似乎不影响药物暴露,因为1200 mg/m²的延长静脉输注或推注给药获得了相似的AUC(分别为13.78±2.90和15.05±1.44 mg·ml⁻¹·min)。在后续疗程中研究的9名儿童中,观察到患者间变异性有限,通过对剂量、AUC和疗程数的多变量分析,未发现AUC与后续疗程之间存在相关性(r = 0.035)。药代动力学参数与先前在成人中报道的相似;然而,观察到卡铂全身清除率与在正常范围内变化的肌酐清除率之间存在弱相关性(r = 0.52,P = 0.03)。(摘要截短为400字)